Ta-1: A Literature Course in Six Modules

How this course is organised

This course runs in six modules and closes with a list of what the studies did not test. It is built around one skill that carries over to every compound page: confirming that the papers attached to a label actually examined the thing the label names. For the string "Ta-1", that check changes the whole reading. In the literature verified for this course, "TA-1" and "Ta-1" function as a probiotic strain code, a soil-bacterium code, an inbred mouse substrain designation, and materials-science notation involving the element symbol for tantalum. None of the verified papers characterised a peptide carrying that name.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions. Every module ends with a short statement of the limits of the evidence, because in this case the limits are the most informative part of the record.

Module 1 — What "Ta-1" refers to and how it has been studied

Definition and class

In informal peptide discussion, the string "Ta-1" is sometimes used as shorthand for thymosin alpha-1 (Tα1), a thymic peptide. No paper in the verified set for this course examined that molecule. Consequently, nothing in this course should be read as a description of a peptide's class, sequence, receptor targets, mechanism, dosing or safety profile. Where a course cannot support a claim with a cited paper, the honest output is an absence, not a paraphrase of something the papers never said.

Origin and forms actually present in the indexed record

The verified papers show four distinct uses of the label. First, as a microbial strain suffix: researchers ran a randomized, double-blinded, placebo-controlled study of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 in relation to gut microbiota and characteristics of metabolic syndrome (PMID 39792908), and a separate group tested Bacillus methylotrophicus TA-1 as a biocontrol agent against Meloidogyne incognita in tomato (PMID 36774575). Second, as an animal substrain code: a 2019 report described senescence-accelerated mice designated SAMP1/TA-1 that were treated repeatedly with lipopolysaccharide and developed a condition resembling hemophagocytic lymphohistiocytosis (PMID 30819910). Third, as chemical notation, as in the synthesis and mechanical characterisation of a nanocrystalline Ta–1.67Al₂O₃ composite produced by pulsed current activated heating (PMID 33715741), in wear testing of ultrafine-grained TiNbZrTaFe/Si biomedical alloys in a simulated physiological solution (PMID 38399037), and in a physics report of superconductivity in a van der Waals layered quasicrystal (PMID 38429267). Fourth, as an unrelated field abbreviation, as in vascular ultrasound used for monitoring inflammatory activity in Takayasu arteritis (PMID 31605660).

Limits of the evidence (Module 1)

The set establishes only that the label is ambiguous across fields. It does not establish a peptide identity, a molecular weight, a sequence, a synthesis route, or a set of commercial or research forms for anything called "Ta-1". Readers looking for those attributes would need primary pharmacology papers that name the molecule explicitly, and none appear in the verified list.

Module 2 — Mechanism as described in the literature

Mechanism sections normally summarise receptor binding, signalling and downstream physiology. Here, the mechanisms described by researchers belong to the entities the papers actually studied.

Microbial and host-interaction mechanisms

In the human probiotic study, the mechanism of interest was modulation of gut microbiota composition in relation to metabolic syndrome characteristics, tested against placebo (PMID 39792908). In the agricultural work, the proposed mechanism was biological suppression of a root-knot nematode in tomato by a bacterial strain rather than a chemical nematicide (PMID 36774575). In the mouse work, the driver was repeated lipopolysaccharide exposure in a senescence-accelerated substrain, which researchers reported produced a hyperinflammatory picture resembling hemophagocytic lymphohistiocytosis (PMID 30819910).

Small-molecule and material mechanisms in the same set

Other verified papers describe mechanisms that have nothing to do with peptide signalling: antimicrobial and immunomodulatory actions of tannic acid supplementation in broilers infected with Salmonella Typhimurium (PMID 36081234), tannic acid crosslinking used to control neomycin delivery from hydrogels in infected wounds (PMID 40292644), and antioxidant-type protection by the carotenoid trans-astaxanthin against rotenone-induced toxicity in Drosophila melanogaster (PMID 35301354).

Limits of the evidence (Module 2)

No verified paper described a receptor, transporter, enzyme or immune pathway engaged by a peptide named Ta-1. Mechanistic statements that circulate informally about such a peptide cannot be traced to this evidence set, and mechanisms demonstrated for a bacterial strain, a polyphenol or a metal composite do not transfer to an unrelated molecule that happens to share an abbreviation.

Module 3 — Reported outcomes by study

The table below records model, endpoints and the direction of the reported result at the level the abstracts support. No numerical doses, percentages or effect sizes are reproduced here, because the verified set cannot support them for a peptide, and quantities should never be attached to the wrong molecule.

Limits of the evidence (Module 3)

Outcomes in this table belong to bacteria, polyphenols, carotenoids, anti-seizure drug combinations, alloys and surgical anatomy. None of them measured an endpoint after administration of a peptide named Ta-1. The human study in the set was a probiotic trial (PMID 39792908), so its results describe a live-microorganism intervention and nothing else.

Module 4 — Ta-1 Side Effects: What Studies Report

Across the verified papers, no study reported adverse events attributable to a peptide named Ta-1, because no verified study administered such a peptide. What the set does contain is instructive about how safety information is generated.

• Human, controlled design: the probiotic study used a randomized, double-blinded, placebo-controlled structure, which is the design type capable of separating intervention-related complaints from background events (PMID 39792908); the abstract-level scope verified here centred on microbiota and metabolic syndrome characteristics rather than an itemised tolerability table.
• Severe outcomes as an induced model, not a drug reaction: in the mouse work, repeated lipopolysaccharide exposure in SAMP1/TA-1 animals was reported to produce a condition resembling hemophagocytic lymphohistiocytosis, which researchers used as a disease model rather than as a toxicity signal for a therapeutic (PMID 30819910).
• Veterinary and agricultural safety framing: the broiler study examined antimicrobial and immunomodulatory effects of tannic acid in infected birds (PMID 36081234), and the nematode study assessed biocontrol efficacy in tomato (PMID 36774575); neither design generates human adverse-event data.
• Toxicology endpoints in other species: protection against rotenone toxicity in flies (PMID 35301354) and seizure control after a sarin insult in rats (PMID 38395364) illustrate hazard-model research that does not translate into human tolerability statements.

Limits of the evidence (Module 4)

An absence of reported adverse events in an unrelated evidence set is not a safety finding. It means the question was never asked about the molecule readers may have in mind. Safety characterisation requires dose-ranging studies, defined exposure durations, systematic adverse-event collection and, ideally, long-term follow-up, none of which appear in this verified list for any peptide.

Module 5 — Pharmacokinetics where data exist

Pharmacokinetic modules normally list route of administration, absorption, peak concentration, half-life, area under the curve, distribution volume, metabolism and elimination. The verified set contains no such parameters for a peptide named Ta-1, and no paper here measured peptide concentrations in plasma or tissue over time.

Two papers do illustrate adjacent concepts. The hydrogel study examined how tannic acid crosslinking influenced neomycin delivery in infected wounds, which is a release-and-delivery question rather than systemic pharmacokinetics (PMID 40292644). The alloy wear study measured material degradation behaviour in a simulated physiological solution, which addresses implant durability rather than drug exposure (PMID 38399037). Neither provides human exposure data for any peptide.

Limits of the evidence (Module 5)

With no absorption, half-life or clearance values in the verified record, no statement can be made about how often, by what route, or in what quantity a peptide named Ta-1 has been studied in humans. Any figure circulating without a primary pharmacokinetic citation should be treated as unsourced.

Module 6 — Regulatory status, stated factually

Regulatory categories are independent of the biology and are worth stating plainly. In the United States, a medicine reaches the market as an approved drug product only with an approved application and label listing its indication, strength and route; approval attaches to a specific product, not to a molecule name used loosely. Materials sold as research use only (RUO) are labelled for laboratory investigation and not for human or veterinary administration, and RUO labelling is not an abbreviated pathway to clinical use. Compounded preparations are governed in the U.S. by the compounding provisions of the Federal Food, Drug, and Cosmetic Act, which limit which bulk substances licensed pharmacies and outsourcing facilities may use; a substance's presence in the scientific literature does not by itself make it eligible for compounding.

Other regimes appear in the verified set. Probiotic strains such as the one evaluated in the randomized human study are typically studied as foods or dietary supplements rather than as approved drugs (PMID 39792908). Agricultural biocontrol agents such as the strain tested against root-knot nematode in tomato fall under pesticide and plant-protection regulation (PMID 36774575), and feed additives studied in poultry sit under animal-feed rules (PMID 36081234). Tantalum-containing alloys evaluated for wear behaviour belong to medical-device regulation rather than drug regulation (PMID 38399037).

Limits of the evidence (Module 6)

None of the verified papers addressed the legal or regulatory status of a peptide named Ta-1 in any jurisdiction, and regulatory classifications change over time and differ by country. This section is general information, not legal advice.

What the studies did not test

Read together, the verified literature indexed under this label did not test any of the following:

1. Administration of a peptide named Ta-1 to humans or animals, at any route or duration.
2. Receptor-level or immune-pathway mechanisms for such a peptide.
3. Clinical endpoints such as infection outcomes, immune reconstitution, oncology outcomes or recovery measures attributable to such a peptide.
4. Pharmacokinetic parameters, bioavailability or dose-response relationships for such a peptide.
5. Systematic adverse-event collection, drug-interaction screening, or use in pregnancy, paediatric or organ-impaired populations.
6. Head-to-head comparison against an approved therapy for any indication.

The transferable lesson is procedural. When a short alphanumeric label returns papers on a probiotic strain (PMID 39792908), a mouse substrain (PMID 30819910), a tantalum composite (PMID 33715741), a quasicrystal (PMID 38429267) and an imaging protocol in Takayasu arteritis (PMID 31605660), the citation trail is describing different research objects. Checking the full molecule name, the model, and the endpoint in each abstract prevents outcomes from one field being carried across into claims about another. This page is educational and does not tell any reader what to do with any substance.

References

• The efficacy of Lacticaseibacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 probiotics in modulating gut microbiota and reducing the risk of the characteristics of metabolic syndrome: A randomized, double-blinded, placebo-controlled study (PLoS One, 2025)
• Biocontrol Efficacy of Bacillus methylotrophicus TA-1 Against Meloidogyne incognita in Tomato (Plant Disease, 2023)
• Senescence-accelerated mice (SAMP1/TA-1) treated repeatedly with lipopolysaccharide develop a condition that resembles hemophagocytic lymphohistiocytosis (Haematologica, 2019)
• Antimicrobial and immunomodulatory effects of tannic acid supplementation in broilers infected with Salmonella Typhimurium (Poultry Science, 2022)
• Experimental Optimization of Tannic Acid-Crosslinked Hydrogels for Neomycin Delivery in Infected Wounds (Polymers, 2025)
• Protective capacity of carotenoid trans-astaxanthin in rotenone-induced toxicity in Drosophila melanogaster (Scientific Reports, 2022)
• Efficacy of a combined anti-seizure treatment against cholinergic established status epilepticus following a sarin nerve agent insult in rats (Toxicology and Applied Pharmacology, 2024)
• Sliding and Fretting Wear Behavior of Biomedical Ultrafine-Grained TiNbZrTaFe/Si Alloys in Simulated Physiological Solution (Materials, 2024)
• Mechanical Properties and Synthesis of Nanocrystalline Ta-1.67Al₂O₃ Composite by Pulsed Current Activated Heating (Journal of Nanoscience and Nanotechnology, 2021)
• Superconductivity in a van der Waals layered quasicrystal (Nature Communications, 2024)
• Vascular ultrasound for monitoring of inflammatory activity in Takayasu arteritis (Clinical Physiology and Functional Imaging, 2020)
• Distal Nerve Transfers in High Peroneal Nerve Lesions: An Anatomical Feasibility Study (Journal of Personalized Medicine, 2023)